Table 2 Description of COVID-19 characteristics among patients with schizophrenia

Patients diagnosed with COVID-19

 Yes

71 (74.7%)

 No

24 (25.3%)

Severity of the COVID-19 infection

 Asymptomatic

32 (45.1%)

 Mild

34 (47.9%)

 Moderate

0 (0.0%)

 Severe

5 (7.0%)

Presence of post-COVID-19 symptoms

 Cough

4 (5.7%)

 Fever

2 (2.9%)

 Dyspnea

14 (20.0%)

 Chest pain

9 (12.9%)

 Diarrhea

4 (5.7%)

 Abdominal pain

6 (8.6%)

 Loss of taste

5 (7.1%)

 Loss of smell

5 (7.1%)

 Sore throat

3 (4.3%)

 Nausea

8 (11.4%)

 Vomiting

3 (4.3%)

 Headache

9 (12.9%)

 Myalgia

7 (10.0%)

 Arthralgia

13 (18.6%)

 Fatigue

37 (52.9%)

 Rash

0 (0%)

Number of post-COVID-19 symptoms

 0

26 (37.1%)

 1

16 (22.9%)

 2

12 (17.1%)

  > 2

16 (22.9%)

Mean ± SD

Duration between the cognitive evaluation at baseline and post-COVID period cognitive assessment by month

20.65 ± 1.47

Duration between the infection by the SARS-CoV-2 virus and post cognitive assessment by month

6.62 ± 1.94